Cost-Utility Analysis of Indocyanine Green Versus Methylene Blue for Sentinel Lymph Node Biopsy in Breast Cancer. (2026)

Peer-Reviewed Study · Lee SH, Kohler A, Tingen J, King CA, Persing SM, Homsy C, Nardello S, Chatterjee A · May 10, 2026

Lee SH et al., 2026-05-10: Cost-utility analysis finding indocyanine green more cost-effective than methylene blue for breast sentinel node biopsy because of fewer complications.

Given lower complication rates despite higher upfront cost, ICG proved more cost-effective than MB in SLNB for breast cancer due to its improved quality-adjusted outcomes.

Lee SH et al., 2026-05-10: Cost-utility analysis finding indocyanine green more cost-effective than methylene blue for breast sentinel node biopsy because of fewer complications. C7 (comparator). Study type: cost-utility analysis built on a systematic PubMed review; Tufts Medical Center, Boston, USA. Model-based, no patients enrolled; 80% probability that ICG is the more cost-effective option. Dose not applicable. Funder/conflicts not stated in the abstract. Bearing CONTRADICTS the reading that methylene blue is the dye of choice: the analysis puts a competing tracer ahead of it on complications and quality-adjusted outcomes, and the 'fewer complications' premise rests on the skin-necrosis reports recorded in MTI-79 and MTI-80. J Surg Oncol 2026;134:41-53. Study type: other.